# Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

Study · id `cardio:ct-nct05880056` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05880056](<https://clinicaltrials.gov/study/NCT05880056>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05880056

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 406 participants.

## Technical summary

Registry record NCT05880056. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-08 (actual); primary completion 2025-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 406 participants (planned count; ClinicalTrials.gov record NCT05880056, source copy `cardio:ctgov-nct05880056-2024-08-19`, retrieved 2026-10-26)
- Started: 2024-08-08 (actual) (ClinicalTrials.gov record NCT05880056, source copy `cardio:ctgov-nct05880056-2024-08-19`, retrieved 2026-10-26)
- Primary completion: 2025-04-01 (anticipated) (ClinicalTrials.gov record NCT05880056, source copy `cardio:ctgov-nct05880056-2024-08-19`, retrieved 2026-10-26)
- Completion: 2025-04-01 (anticipated) (ClinicalTrials.gov record NCT05880056, source copy `cardio:ctgov-nct05880056-2024-08-19`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05880056, source copy `cardio:ctgov-nct05880056-2024-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05880056-2024-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
- Acronym: BETTER
- Condition: Essential Hypertension
- Intervention (Drug): Nerkardou (5 mg) & (10 mg)
- Lead sponsor: Genuine Research Center, Egypt
- Lead sponsor class: INDUSTRY
- Collaborator: Nerhadou International for pharmaceutical & Nutraceutical, Egypt
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 705a5ee9f6aa85cf471049f33f6acf99414efb67bf1426103cb83eaea4e61a50
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
